TY - JOUR
T1 - Histopathological and molecular features of late relapses in non-seminomas
AU - Mayer, Frank
AU - Wermann, Hendrik
AU - Albers, Peter
AU - Stoop, Hans
AU - Gillis, Ad J M
AU - Hartmann, Jörg T
AU - Bokemeyer, C Carsten
AU - Oosterhuis, J Wolter
AU - Looijenga, Leendert H J
AU - Honecker, Friedemann
N1 - © 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.
PY - 2011/3
Y1 - 2011/3
N2 - OBJECTIVE: • To describe the histopathological types of late relapses of germ cell tumours and to search for molecular markers associated with chemotherapy resistance.PATIENTS AND METHODS: • Samples from 14 patients with late relapse from a non-seminoma were analysed. • Archival tumour tissue was gathered at intial diagnosis (n= 9) and at relapse (n= 9), mostly after previous treatment with chemotherapy. • In addition to routine histopathology, tumours were analysed for microsatellite instability and screened for mutations in the KRAS and BRAF genes.RESULTS: • Relapse occurred after 76.5 months (median, range: 24-209 months). • The histology in relapse was pure yolk sac tumour in four of the nine patients analysed. • Three had a non-germ cell malignancy, one was a mixed non-seminoma and one was a pure mature teratoma. • One sample with non-germ cell malignancy originated from a yolk sac tumour without any evidence of teratoma. • In four of 12 evaluable patients, high-level microsatellite instability was observed. • All patients were KRAS wild-type but four showed a BRAF mutation at V600E.CONCLUSIONS: • Many late relapses of germ cell tumours show pure yolk sac histology. • Non-germ cell malignancies do not necessarily develop from teratoma but can also arise from yolk sac histology. • The biology underlying chemotherapy resistance in late relapse could be related to a high incidence of microsatellite instability and BRAF mutation V600E, which were found in half of the patients.
AB - OBJECTIVE: • To describe the histopathological types of late relapses of germ cell tumours and to search for molecular markers associated with chemotherapy resistance.PATIENTS AND METHODS: • Samples from 14 patients with late relapse from a non-seminoma were analysed. • Archival tumour tissue was gathered at intial diagnosis (n= 9) and at relapse (n= 9), mostly after previous treatment with chemotherapy. • In addition to routine histopathology, tumours were analysed for microsatellite instability and screened for mutations in the KRAS and BRAF genes.RESULTS: • Relapse occurred after 76.5 months (median, range: 24-209 months). • The histology in relapse was pure yolk sac tumour in four of the nine patients analysed. • Three had a non-germ cell malignancy, one was a mixed non-seminoma and one was a pure mature teratoma. • One sample with non-germ cell malignancy originated from a yolk sac tumour without any evidence of teratoma. • In four of 12 evaluable patients, high-level microsatellite instability was observed. • All patients were KRAS wild-type but four showed a BRAF mutation at V600E.CONCLUSIONS: • Many late relapses of germ cell tumours show pure yolk sac histology. • Non-germ cell malignancies do not necessarily develop from teratoma but can also arise from yolk sac histology. • The biology underlying chemotherapy resistance in late relapse could be related to a high incidence of microsatellite instability and BRAF mutation V600E, which were found in half of the patients.
KW - Adolescent
KW - Adult
KW - Biomarkers, Tumor
KW - Drug Resistance, Neoplasm/genetics
KW - Humans
KW - Male
KW - Microsatellite Instability
KW - Middle Aged
KW - Mutation/genetics
KW - Neoplasm Recurrence, Local/drug therapy
KW - Neoplasms, Germ Cell and Embryonal/drug therapy
KW - Orchiectomy/methods
KW - Proto-Oncogene Proteins/genetics
KW - Proto-Oncogene Proteins B-raf/genetics
KW - Proto-Oncogene Proteins p21(ras)
KW - Testicular Neoplasms/drug therapy
KW - Time Factors
KW - Young Adult
KW - ras Proteins/genetics
UR - https://www.scopus.com/pages/publications/79952609650
U2 - 10.1111/j.1464-410X.2010.09631.x
DO - 10.1111/j.1464-410X.2010.09631.x
M3 - Article
C2 - 20955261
SN - 1464-4096
VL - 107
SP - 936
EP - 943
JO - BJU international
JF - BJU international
IS - 6
ER -